Corvus Prescription drugs, Inc. (CRVS) This autumn 2025 Earnings Name March 12, 2026 4:30 PM EDT
Firm Members
Leiv Lea – Chief Monetary Officer
Richard Miller – Co-Founder, President, CEO & Chairman of the Board
Convention Name Members
Zack Kubow – Actual Chemistry, Inc.
Jiale Tune – Jefferies LLC, Analysis Division
Li Wang Watsek – Cantor Fitzgerald & Co., Analysis Division
Graig Suvannavejh – Mizuho Securities USA LLC, Analysis Division
Jeffrey Jones – Oppenheimer & Co. Inc., Analysis Division
Aydin Huseynov – Ladenburg Thalmann & Co. Inc., Analysis Division
Xun Lee – H.C. Wainwright & Co, LLC, Analysis Division
Presentation
Operator
Good afternoon, everybody, and thanks for standing by, and welcome to the Corvus Prescription drugs Fourth Quarter and Full Yr 2025 Enterprise Replace and Monetary Outcomes Convention Name. (Operator Directions)
It’s now my pleasure to show the decision over to Mr. Zack Kubow from Actual Chemistry. Please go forward, sir.
Zack Kubow
Actual Chemistry, Inc.
Thanks, operator, and good afternoon, everybody. Thanks for becoming a member of us for the Corvus Prescription drugs Fourth Quarter and Full Yr 2025 Enterprise Replace and Monetary Outcomes Convention Name. On the decision to debate the outcomes and enterprise updates are Richard Miller, Chief Govt Officer; Leiv Lea, Chief Monetary Officer; Jeff Arcara, Chief Enterprise Officer; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences.
The chief workforce will open the decision with some ready remarks adopted by a question-and-answer interval. I wish to remind everybody that feedback made by administration at the moment and solutions to questions will embrace forward-looking statements. Ahead-looking statements are based mostly on estimates and assumptions as of at the moment and are topic to dangers and uncertainties which will trigger precise outcomes to vary materially from these expressed or implied by these statements, together with the dangers and uncertainties described in Corvus’ annual report on Type 10-Ok for the yr ended December 31, 2025, and